GLI GLI Quality Tool
GLI Quality Tool — Version 2.0

Building A Quality Policy For TB Laboratories With The GLI Roadmap

A quality policy gives a tuberculosis laboratory a clear statement of what reliable, safe and clinically useful testing means in daily practice. It turns broad commitments into responsibilities for specimen reception, microscopy, molecular testing, culture, drug susceptibility testing, reporting and corrective action.

For Australian laboratories, the policy should fit both a mature accreditation environment and the practical realities of TB control. A metropolitan reference service may work within a large public hospital network, while a regional laboratory may depend on overnight transport, shared staff and specialist support from a capital city.

The GLI Quality Tool provides a staged way to build that policy. Its four phases help a laboratory move from understanding its current position to planning, implementing and sustaining improvements across the twelve Quality Systems Essentials (QSEs).

Define The Policy’s Purpose And Scope

Start with a short policy that explains why quality matters for TB services. It should commit the laboratory to accurate, timely, safe and traceable results that support diagnosis, treatment selection, infection prevention and public health action. The wording should cover every activity that can affect a patient result, including referral testing and results received from external providers.

The scope should name the tests and services included. These may include smear microscopy, nucleic acid amplification, culture, identification, phenotypic or molecular drug resistance testing, and specimen referral. Include pre-examination activities such as collection instructions, packaging and transport, because a technically excellent test cannot compensate for a leaking container, an inadequate sample or an unlabelled specimen.

Assign ownership at the beginning. The laboratory director or senior clinical lead should approve the policy, while a quality manager coordinates implementation. Section leaders, authorised scientists, specimen reception staff, couriers, clinicians and public health teams all need defined responsibilities. In Australia, those responsibilities should align with the laboratory’s NATA accreditation arrangements and relevant state or territory procedures.

Use Phase One To Establish A Baseline

The first GLI phase is a structured starting point: understand the laboratory, its risks and its existing quality practices. Review current documents, incident records, turnaround times, staff competencies, equipment logs, internal quality control and external quality assessment results. Compare what staff actually do with what procedures say they should do.

Map the patient and specimen pathway from collection to final report. Identify points where delays, transcription errors, contamination, lost samples or unclear escalation could occur. For a remote service in Western Australia, the risk profile may include long road or air freight routes. In northern Queensland or the Northern Territory, seasonal weather can affect transport schedules and access to specialist services.

Use the GLI checklists as evidence-gathering tools rather than treating them as a one-off audit. Record whether each requirement is fully met, partly met or absent, then retain examples such as approved procedures, training records and temperature logs. This baseline lets the laboratory set realistic priorities instead of creating a policy that promises controls it cannot yet support.

Translate The Twelve Essentials Into Commitments

The twelve QSEs provide the content framework for a complete quality management system. The policy should address organisation, personnel, equipment, purchasing and inventory, process management, information management, documents and records, customer focus, assessment, nonconforming event management, continual improvement and facilities and safety.

Avoid listing the QSE names without explaining how they apply to TB work. A meaningful commitment might state that only trained and authorised staff perform critical procedures, that equipment is maintained before use, that records are legible and retrievable, and that unexpected results are reviewed before release. Each commitment should have an owner and a way to demonstrate performance.

Australia’s low TB incidence can make routine exposure to complex cases less frequent in some laboratories. The policy should therefore protect competence through documented induction, supervised practice, refresher training, competency assessment and access to experienced referral scientists. It should also reflect culturally safe engagement with Aboriginal and Torres Strait Islander communities and appropriate communication with people from migrant and refugee backgrounds.

Build A Practical Implementation Plan

In the second GLI phase, convert the baseline into an improvement plan. Rank gaps by patient and staff safety, effect on clinical decisions, regulatory importance and feasibility. A missing biosafety control or unreliable result-reporting process normally deserves attention before a cosmetic document redesign.

Create actions that are specific enough to monitor. For example, an action might require specimen acceptance criteria to be reviewed, a new temperature monitoring system to be validated, or a critical-result escalation pathway to be tested. Name the responsible person, required resources, due date, evidence of completion and approval authority.

A staged plan works well when resources are limited. One quarter may focus on document control and specimen reception, the next on equipment and competency, followed by assessment and continual improvement. State and territory laboratories can coordinate shared procedures and training with reference centres, while smaller services can use referral networks rather than attempting to build every specialised capability locally.

Implement Controlled Procedures And Safe Workflows

The third phase is where the policy becomes visible in routine work. Approve standard operating procedures through document control, remove obsolete copies and make current versions available where staff perform the task. Procedures should describe acceptance and rejection criteria, controls, reporting rules, contamination prevention, troubleshooting and escalation.

Safety commitments need to be operational. Include risk assessments, engineering controls, personal protective equipment, spill response, exposure management, waste handling and incident reporting. Work with the laboratory’s biological safety advisers and ensure that procedures reflect the facility’s containment arrangements and the organisms or processes handled.

Information management also requires careful implementation. Define who may authorise, amend, release and correct a result. Set rules for urgent communication, amended reports, downtime procedures and audit trails. The laboratory can use reporting timeliness guidance to make result delivery a measurable part of the quality policy, rather than an informal expectation.

Measure Performance And Manage Risk

The fourth phase focuses on sustaining and improving the system. Choose a small dashboard of indicators that reflects clinical and laboratory priorities. Useful measures include specimen rejection, contamination, invalid molecular results, equipment downtime, proficiency testing performance, critical-result notification, report correction and turnaround time from receipt to clinician notification.

Set a definition for each indicator. “Fast reporting” is too vague; a laboratory might measure the percentage of positive molecular results communicated within an agreed timeframe, with exclusions documented. Review results by test type, location, shift and referral pathway where this helps identify inequity or operational weaknesses.

Use incidents and nonconformities as sources of learning. Apply root-cause analysis to recurring problems, document immediate containment, and verify whether corrective action worked. A courier delay, for example, may require more than reminding staff to package samples correctly; the underlying cause could be a collection timetable that does not match the flight schedule from a regional community.

Link Quality Activities To Clinical And Public Health Needs

A TB quality policy should connect laboratory performance with the decisions made by clinicians and public health services. Define how presumptive TB results, rifampicin resistance findings, culture confirmation and drug susceptibility results are communicated. Clarify who contacts the treating team and who notifies the relevant public health unit under local arrangements.

Customer focus includes more than formal complaints. Seek feedback from respiratory physicians, infectious diseases teams, microbiologists, nurses, specimen collection centres and public health practitioners. Ask whether reports are understandable, whether interpretive comments are useful and whether urgent findings reach the right person at the right time.

The GLI quality management resource can support this broader view of quality management. It is particularly useful when a laboratory needs to connect policy statements with phase-specific checklists, practical guidance and downloadable materials. In Australia, this approach can help align local procedures with network-wide expectations without ignoring the needs of rural and remote services.

Review, Communicate And Keep Improving

Schedule formal policy review at least annually and sooner when there is a major change in testing, staffing, equipment, accreditation requirements or public health guidance. Review whether objectives were met, whether risks have changed and whether staff still understand their responsibilities. Record the review, decisions and approved revisions.

Communication should be regular and practical. Discuss indicators at quality meetings, display relevant trends for staff, and include quality responsibilities in induction and performance conversations. Recognise improvements, such as fewer rejected specimens or faster communication of resistance results, so quality work remains connected to patient care rather than becoming paperwork.

The roadmap is intended to support progressive improvement, not a single certification exercise. Laboratories can use the feedback channel to share experience with the tool and identify where guidance could better reflect varied resource settings. That exchange is valuable for Australian services working across metropolitan, regional and remote environments.

Adopt the policy through a controlled approval process, then begin with a documented baseline and a manageable set of high-risk actions. Use the GLI phases and QSEs to organise evidence, assign accountability and review results. When quality is built into everyday TB laboratory decisions, the policy becomes a working safeguard for patients, staff, clinicians and public health teams.